CE: Sodium-Glucose Co-transporter 2 Inhibitors: Safety Considerations and Clinical Implications for Healthcare Providers
Sodium-Glucose Co-transporter-2 inhibitors have been adopted into the most recent American Diabetes Association Guidelines as a now integral part of diabetes care. These medications may be involved in effective strategies to lower glycosylated hemoglobin (A1C), blood glucose, long-term neuropathies and other diabetic complications. Specifically, these drugs have recently been accepted as the drugs of choice in diabetes care for those with cardiovascular comorbidities. Additionally, recent updates regarding Black Box Warnings with canagliflozin have stated it may cause long term increases in the overall number of amputations. Knowledge concerning the new guidelines and the clinical implications with this class of drugs is essential to providing patient care and optimizing outcomes for patients suffering from type two diabetes mellitus.